-
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
Int J Cancer. 1999 Aug 27;82(5):640-3
PMID: 10417759
-
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
Cancer Res. 1998 Apr 15;58(8):1719-22
PMID: 9563489
-
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
Oncogene. 2000 Mar 16;19(12):1547-55
PMID: 10734314
-
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6
PMID: 16046538
-
Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met.
Biochem J. 1998 Nov 15;336 ( Pt 1):235-9
PMID: 9806906
-
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Nat Genet. 1997 May;16(1):68-73
PMID: 9140397
-
Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx.
Oncogene. 2003 Nov 20;22(52):8519-23
PMID: 14627992
-
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.
Cancer Res. 1999 Jan 15;59(2):307-10
PMID: 9927037
-
The protein kinase complement of the human genome.
Science. 2002 Dec 6;298(5600):1912-34
PMID: 12471243
-
Two mutations affecting conserved residues in the Met receptor operate via different mechanisms.
Oncogene. 2000 Mar 2;19(10):1354-61
PMID: 10713677
-
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
Cancer Cell. 2003 Apr;3(4):347-61
PMID: 12726861
-
Met, metastasis, motility and more.
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
PMID: 14685170
-
Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Oncogene. 1999 Apr 8;18(14):2343-50
PMID: 10327054
-
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood. 2005 Apr 1;105(7):2640-53
PMID: 15618470
-
Automated protein crystal structure determination using ELVES.
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1537-42
PMID: 14752198
-
Met provides essential signals for liver regeneration.
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10608-13
PMID: 15249655
-
A novel germ line juxtamembrane Met mutation in human gastric cancer.
Oncogene. 2000 Oct 12;19(43):4947-53
PMID: 11042681
-
Crystallography & NMR system: A new software suite for macromolecular structure determination.
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21
PMID: 9757107
-
Improved methods for building protein models in electron density maps and the location of errors in these models.
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
PMID: 2025413
-
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.
Nat Genet. 1998 Sep;20(1):66-9
PMID: 9731534
-
Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours.
Oncogene. 1998 Aug 13;17(6):733-9
PMID: 9715275
-
Integration of macromolecular diffraction data.
Acta Crystallogr D Biol Crystallogr. 1999 Oct;55(Pt 10):1696-702
PMID: 10531519
-
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12654-9
PMID: 14559966
-
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Cancer Res. 2002 Aug 1;62(15):4236-43
PMID: 12154025
-
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Cancer Lett. 2005 Jul 8;225(1):1-26
PMID: 15922853
-
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor.
Cancer Cell. 2004 Jul;6(1):61-73
PMID: 15261142
-
Refinement of macromolecular structures by the maximum-likelihood method.
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
PMID: 15299926
-
Met decoys: will cancer take the bait?
Cancer Cell. 2004 Jul;6(1):5-6
PMID: 15261136
-
Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity.
J Biol Chem. 2003 Aug 1;278(31):29352-8
PMID: 12746450
-
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.
J Cell Biol. 2001 May 28;153(5):1023-34
PMID: 11381087
-
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
Mol Cell. 2001 Nov;8(5):995-1004
PMID: 11741535
-
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Oncogene. 1999 Sep 16;18(37):5221-31
PMID: 10498872
-
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Nat Biotechnol. 2005 Feb;23(2):201-7
PMID: 15685167
-
The purification and characterization of the catalytic domain of Src expressed in Schizosaccharomyces pombe. Comparison of unphosphorylated and tyrosine phosphorylated species.
Eur J Biochem. 1996 Sep 15;240(3):756-64
PMID: 8856081
-
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Oncogene. 2004 Jul 8;23(31):5387-93
PMID: 15064724
-
Cancer therapy: can the challenge be MET?
Trends Mol Med. 2005 Jun;11(6):284-92
PMID: 15949770
-
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Cancer Res. 2003 Oct 1;63(19):6272-81
PMID: 14559814
-
Implementation of molecular replacement in AMoRe.
Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1367-72
PMID: 11567147
-
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17198-203
PMID: 15557554
-
Regulation of the wild-type and Y1235D mutant Met kinase activation.
Biochemistry. 2005 Nov 1;44(43):14110-9
PMID: 16245927
-
Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.
EMBO J. 1997 Sep 15;16(18):5572-81
PMID: 9312016
-
Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor.
EMBO J. 2004 Jun 16;23(12):2325-35
PMID: 15167892
-
Activating mutations for the met tyrosine kinase receptor in human cancer.
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50
PMID: 9326629
-
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
Cancer Res. 2002 Dec 1;62(23):7025-30
PMID: 12460923
-
Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling.
Oncogene. 1999 Sep 9;18(36):5120-5
PMID: 10490849
-
The Sema domain of Met is necessary for receptor dimerization and activation.
Cancer Cell. 2004 Jul;6(1):75-84
PMID: 15261143
-
K252a inhibits the oncogenic properties of Met, the HGF receptor.
Oncogene. 2002 Jul 25;21(32):4885-93
PMID: 12118367
-
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.
Cell. 1994 Apr 22;77(2):261-71
PMID: 7513258
-
Missense mutation of the MET gene detected in human glioma.
Mod Pathol. 2000 Sep;13(9):973-7
PMID: 11007037
-
Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Oncogene. 1999 Jul 22;18(29):4275-81
PMID: 10435641